Race Oncology Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Race Oncology.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	16.2%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate

Jan 23

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Oct 05

Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth

Jun 20

We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow

Feb 17

Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation

Oct 14

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Apr 01

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Race Oncology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

ASX:RAC - Analysts future estimates and past financials data (AUD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	6	-11	-13	-13	N/A
9/30/2023	4	-11	-12	-12	N/A
6/30/2023	3	-10	-11	-11	N/A
3/31/2023	2	-10	-10	-10	N/A
12/31/2022	1	-11	-9	-9	N/A
9/30/2022	1	-11	-8	-8	N/A
6/30/2022	1	-11	-6	-6	N/A
3/31/2022	1	-10	-6	-6	N/A
12/31/2021	1	-9	-6	-6	N/A
9/30/2021	1	-8	-5	-5	N/A
6/30/2021	0	-6	-5	-5	N/A
3/31/2021	0	-5	-4	-4	N/A
12/31/2020	0	-4	-3	-3	N/A
9/30/2020	0	-4	-3	-3	N/A
6/30/2020	0	-4	-2	-2	N/A
3/31/2020	0	-3	-2	-2	N/A
12/31/2019	0	-3	-2	-2	N/A
9/30/2019	0	-3	-2	-2	N/A
6/30/2019	0	-4	-3	-3	N/A
3/31/2019	0	-4	-3	-3	N/A
12/31/2018	0	-5	-3	-3	N/A
9/30/2018	0	-6	-3	-3	N/A
6/30/2018	0	-6	-4	-4	N/A
3/31/2018	0	-6	-4	-4	N/A
12/31/2017	0	-6	-4	-4	N/A
9/30/2017	0	-5	N/A	-3	N/A
6/30/2017	N/A	-4	N/A	-2	N/A
3/31/2017	N/A	-3	N/A	-2	N/A
12/31/2016	N/A	-2	N/A	-1	N/A
9/30/2016	N/A	-1	N/A	-1	N/A
6/30/2016	N/A	0	N/A	0	N/A
3/31/2016	N/A	0	N/A	0	N/A
12/31/2015	N/A	0	N/A	0	N/A
9/30/2015	N/A	0	N/A	0	N/A
6/30/2015	N/A	0	N/A	0	N/A
6/30/2014	N/A	0	N/A	0	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if RAC's forecast earnings growth is above the savings rate (2.2%).

Earnings vs Market: Insufficient data to determine if RAC's earnings are forecast to grow faster than the Australian market

High Growth Earnings: Insufficient data to determine if RAC's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if RAC's revenue is forecast to grow faster than the Australian market.

High Growth Revenue: Insufficient data to determine if RAC's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if RAC's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Race Oncology Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

New minor risk - Shareholder dilution

New major risk - Financial position

We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate

Race Oncology Limited Appoints Daniel Tillett as Chief Executive Officer

Race Oncology Limited, Annual General Meeting, Nov 27, 2023

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

New minor risk - Share price stability

New minor risk - Financial data availability

Race Oncology Limited Announces Board Changes

New minor risk - Market cap size

Race Oncology Limited Announces Board Changes

Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth

Race Oncology Limited Appoints Michelle Rashford Chief Medical Officer, Effective 1 July 2023

We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow

Race Oncology Limited Appoints Damian Clarke-Bruce as Director

Race Oncology Limited Receives Human Ethics Approval for Observational Cardioprotection Breast Cancer Trial

Race Oncology Limited, Annual General Meeting, Feb 21, 2023

Board Member recently bought AU$50k worth of stock

Board Member recently bought AU$99k worth of stock

Race Oncology Limited Appoints Damian Clarke-Bruce as Managing Director, Effective 1 February 2023

Race Oncology Limited Announces It Has Submitted A Human Ethics Application to Hunter New England Human Research Ethics Committee Seeking Approval to Commence the Observational Stage of A Planned Phase 1/2B Clinical Trial of Zantrene

Race Oncology Limited Appoints Daniel (Danny) Sharp as an Independent Non-Executive Director

Race Oncology Limited Receives Positive Guidance on Zantrene Via Pre-IND Meeting with US FDA

High number of new and inexperienced directors

Race Oncology Ltd Announces Management Changes

Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation

Race Oncology Limited, Annual General Meeting, Nov 24, 2022

Race Oncology Limited Develops Improved Iv Formulation of Zantrene

Race Oncology Limited Initiates New Drug Discovery Program

Board Member recently bought AU$165k worth of stock

Race Oncology Limited Shares Further Interim Results from Preclinical Cardioprotection Program in Collaboration with Researchers from the University of Newcastle

Race Oncology Limited Announces Interim Results from its Preclinical Melanoma Research Program

Race Oncology Limited Expands FTO Targeting Phase 1b/2a Extramedullary AML & MDS Trial to Europe

Race Oncology Limited Announces the Dose Escalation Phase 1b Stage of the Relapsed or Refractory Acute Myeloid Leukaemia (R/R AML) Trial Running At the Chaim Sheba Medical Centre, Israel

Race Oncology Limited Appoints Guy Breitenbucher to Its Scientific Advisory Board

Race Oncology Limited Receives Governance Approval for AML EMD & MDS Trial

High number of new and inexperienced directors

Race Oncology Limited Receives Human Ethics Approval for Its Open Label Clinical Trial of Zantrene in Patients with Extramedullary Acute Myeloid Leukaemia or High-Risk Myelodysplastic Syndrome

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Race Oncology Limited Announces Preclinical & Clinical Programs Update

Board Member recently bought AU$56k worth of stock

Race Oncology Limited Announces MD Anderson Cancer Center Collaborators Publish Peer Reviewed AML Preclinical Study on Zantrene

Race Oncology Limited Appoints Christina Manfre as Chief Financial Officer

Non-Independent Non-Executive Chairman recently sold AU$995k worth of stock

Board Member recently bought AU$59k worth of stock

Insider recently sold AU$4.4m worth of stock

Race Oncology Limited Announces Interim Results from the Zantrene® Preclinical Heart Safety Research Program Led by Eminent Cardiotoxicity Researchers, Associate Professors Aaron Sverdlov and Doan Ngo

Non-Independent Non-Executive Chairman exercised options to buy AU$9.8m worth of stock.

Non-Independent Non-Executive Chairman recently bought AU$710k worth of stock

Non-Executive Chairman recently sold AU$193k worth of stock

Non-Executive Chairman exercised options to buy AU$5.7m worth of stock.

Insider recently sold AU$4.3m worth of stock

Race Oncology Limited Executes Contract to Commence Phase 1b/2 AML Trial at Chaim Sheba Israel

Insider recently sold AU$4.8m worth of stock

We're Hopeful That Race Oncology (ASX:RAC) Will Use Its Cash Wisely

Insider recently sold AU$6.6m worth of stock

Race Oncology Limited Announces Compelling Preclinical Breast Cancer Results

Insider recently sold AU$2.1m worth of stock

What Percentage Of Race Oncology Limited (ASX:RAC) Shares Do Insiders Own?

New 90-day high: AU$3.29

Race Oncology Limited Announces Positive Early Preclinical Ovarian Cancer Results

Professor Borje Andersson to Resign as Chief Medical Officer of Race Oncology Limited

Race Oncology Limited Appoints Mary Harney as Non-Executive Director

New 90-day high: AU$2.48

How Much Are Race Oncology Limited (ASX:RAC) Insiders Taking Off The Table?

Race Oncology Limited Announces Borje Andersson Resigns as an Executive Director

Race Oncology Limited Announces Breast Cancer Clinical Trial Program Initiated

New 90-day high: AU$1.30

Race Oncology Limited Reports Phase II Bisantrene Trial Data to be presented at ASH 2020

Race Oncology Limited Announces Director Resignations

New 90-day low: AU$0.76

Race Oncology Limited Appoints Borje S. Andersson as Chief Medical Officer and Executive Director

Race Oncology Limited Appoints Phil Lynch as Chief Executive Officer

Race Oncology Limited announced that it expects to receive AUD 3 million in funding from Merchant Funds Management Pty Ltd and other investors

Earnings and Revenue Growth Forecasts